Abstract
Human papillomaviruses (HPV) are known as the primary cause of cervical cancer. Most HPV infections resolve spontaneously, but those that persist may lead to the development of precancerous abnormalities and, if left untreated, may progress to cancer. Papillomaviruses are members of large family of viruses known as Papovaviridae and HPV is a relatively small virus containing non-enveloped double-stranded (ds) DNA. A number of tests for HPV detection have evolved and the newer RNA based amplification tests detect not only the presence of viral genome but also the viral activity in infected cells. HPV testing is indicated as a primary screening modality, for triaging of minor cytological abnormalities and for follow up of women treated for cervical dysplasia. The chapter gives a detailed account of all the tests used for detection of HPV as well as the latest guidelines for management of women who turn out to be test positive.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Iftner T, Villa LL. Human papillomavirus technologies. J Natl Cancer Inst Monogr. 2003;31:80–5.
Internet: web2.mendelu.cz; prace je spojena’s projektum CEITEC CZ.1.05/1.1.00/02.0068.
Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res. 2003;9:6469–75.
Stoler MH, Wolinsky SM, Whitbeck A, Broker TR, Chow L. Differentiation linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message specific RNA probes. Virology. 1997;172:331–40.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.
Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357–61.
Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. JAMA. 2002;14:1749–59.
Lorincz A, Anthony J. Advances in HPV detection by hybrid capture [letter]. Papillomavirus Rep. 2001;145:54–8.
Molden T, Kraus I, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection. Cancer Epidemiol Biomarkers Prev. 2005;14(2):367–73.
Dockter J, Schroder A, Hill C, et al. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009;45(S1):S55–61.
Molden T, Nygard JF, Kraus I, et al. Predicting CIN 2+ when detecting HPV mRNA and DNA by PreTect HPV –proofer and consensus PCR: a 2 year follow up of women with ASCUS or LSIL pap smear. Int J Cancer. 2005;114(6):973–6.
Khan MJ, Castle P, Sherman M, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type- specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–9.
Boehmer G, et al. A population-based observational study comparing cervista and hybrid capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off. BMC Infect Dis. 2014;14:674–80.
Internet: http://molecular.roche.com/assays/pages/cobasHPVTest.aspx.
Qiao YL, Sellors JW, Eder PS, Bao YP, et al. Anew HPV –DNA test for cervical cancer screening in developing regions: a cross sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9:929–36.
Gravitt PE, Belinson JL, Salmeron J, et al. Looking ahead: a case of human papillomavirus testing of self -sampled vaginal specimens as a cervical cancer screening strategy. Intl Cancer. 2011;129(3):517–27.
Jeronimo J, Bansil P, Lim J, et al. A multi –country evaluation of care HPV testing, visual inspection with acetic acid and pap testing for the detection of cervical pre cancer and cancer. Int J Gynecol Cancer. 2014;24(3):576–85.
Cuzick J, Clavel C, Petry KU. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.
Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulas G, Daponte A, et al. Primary screening for cervical cancer based on high-risk HPV detection and HPV 16 and HPV 18 genotyping in comparison to cytology. PLoS One. 2015;10(3):e0119755. doi:10.1371/journal.pone.0119755.
Castle PE, Lorinez AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high –grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003;41:4022–30.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–72.
Ogilive GS, Krajden M, Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid based cytology: result of randomized control trial. Br J Cancer. 2012;107(12):1917–24.
Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst. 2015;107(2). pii: dju423.
Stoler MH, Wright TC, Sharma A, et al. High risk human papillomavirus testing in women with ASCUS cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468–75.
Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18(23):1–196.
Huh WK, Ault KA, Chelmow D, Davey DD, et al. Use of primary high risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;125(2):330–7.
Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127(8):946–9.
Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev. 2013;3:CD008054. doi:10.1002/14651858.CD008054.pub2.
Paraskevaidis E, Abryn M, Sotiriadis A, Diakomanolis E, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004;30(2):205–11.
Zielinski GD, Bais AG, Helmerhorst TJ, Erheijen RH, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol. 2004;59:543–53.
Massad S, Einstein M, Huh WK, Katki HA, Kinney WK, et al. 2012 updated Consensus guidelines for the management of abnormal cervical screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Mehta, S., Dixit, S.M. (2017). HPV Detection and Clinical Implications. In: Mehta, S., Sachdeva, P. (eds) Colposcopy of Female Genital Tract. Springer, Singapore. https://doi.org/10.1007/978-981-10-1705-6_6
Download citation
DOI: https://doi.org/10.1007/978-981-10-1705-6_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-1704-9
Online ISBN: 978-981-10-1705-6
eBook Packages: MedicineMedicine (R0)